Found: 21
Select item for more details and to access through your institution.
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 106, doi. 10.1111/dom.14555
- By:
- Publication type:
- Article
A novel hypothesis linking low‐grade ketonaemia to cardio‐renal benefits with sodium‐glucose cotransporter‐2 inhibitors.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 3, doi. 10.1111/dom.14562
- By:
- Publication type:
- Article
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 125, doi. 10.1111/dom.14558
- By:
- Publication type:
- Article
Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 115, doi. 10.1111/dom.14557
- By:
- Publication type:
- Article
Off‐label use of sodium glucose co‐transporter inhibitors among adults in type 1 diabetes exchange registry.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 171, doi. 10.1111/dom.14556
- By:
- Publication type:
- Article
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 135, doi. 10.1111/dom.14559
- By:
- Publication type:
- Article
Pharmacodynamics and pharmacokinetics of extended‐release metformin in patients with type 2 diabetes and chronic kidney disease stage 3B.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 166, doi. 10.1111/dom.14554
- By:
- Publication type:
- Article
The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 148, doi. 10.1111/dom.14553
- By:
- Publication type:
- Article
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 94, doi. 10.1111/dom.14551
- By:
- Publication type:
- Article
Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 82, doi. 10.1111/dom.14550
- By:
- Publication type:
- Article
Glucose‐dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double‐blind, placebo‐controlled, crossover clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 142, doi. 10.1111/dom.14545
- By:
- Publication type:
- Article
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 61, doi. 10.1111/dom.14548
- By:
- Publication type:
- Article
Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 160, doi. 10.1111/dom.14547
- By:
- Publication type:
- Article
Antiobesity therapeutics with complementary dual‐agonist activities at glucagon and glucagon‐like peptide 1 receptors.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 50, doi. 10.1111/dom.14546
- By:
- Publication type:
- Article
Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 72, doi. 10.1111/dom.14549
- By:
- Publication type:
- Article
Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 42, doi. 10.1111/dom.14544
- By:
- Publication type:
- Article
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 34, doi. 10.1111/dom.14543
- By:
- Publication type:
- Article
A single bout of cycling exercise induces nucleosome repositioning in the skeletal muscle of lean and overweight/obese individuals.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 21, doi. 10.1111/dom.14541
- By:
- Publication type:
- Article
Are novel glucose‐lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta‐trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 154, doi. 10.1111/dom.14540
- By:
- Publication type:
- Article
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 12, doi. 10.1111/dom.14539
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 1, doi. 10.1111/dom.14425
- Publication type:
- Article